CRISPR Therapeutics
CRSP
CRSP
276 hedge funds and large institutions have $2.91B invested in CRISPR Therapeutics in 2020 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 93 increasing their positions, 62 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
7% more funds holding
Funds holding: 257 → 276 (+19)
6.02% more ownership
Funds ownership: 58.44% → 64.46% (+6%)
13% less call options, than puts
Call options by funds: $76.8M | Put options by funds: $88.7M
Holders
276
Holding in Top 10
6
Calls
$76.8M
Puts
$88.7M
Top Buyers
| 1 | +$162M | |
| 2 | +$42.4M | |
| 3 | +$29.3M | |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$26.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.8M |
Top Sellers
| 1 | -$21.3M | |
| 2 | -$16.9M | |
| 3 | -$14.7M | |
| 4 |
GTP
Global Thematic Partners
New York
|
-$14.1M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$11.1M |